First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Published Date: 02 Feb 2024

Out of 35 evaluable patients, 16 showed responses to cabotezantinib-pembrolizumab; one patient was still required.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment

2.

FDA Expands Approval of Osimertinib in Lung Cancer

3.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

4.

In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.

5.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot